Latest News

Anticancer agents - Breast Cancer - Immunotherapy

Atezolizumab Plus Nab-Paclitaxel Boost Metastatic Triple-Negative Breast Cancer Survival

  • 21 Oct 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

The addition of atezolizumab to nab-paclitaxel results in significantly longer progression-free survival for patients with treatment-naïve metastatic triple-negative breast cancer, especially among those with PD-L1-positive disease

Watch the ESMO Video Highlight on this study

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

 

view detailsof Atezolizumab Plus Nab-Paclitaxel Boost Metastatic Triple-Negative Breast Cancer Survival

Anticancer agents - Breast Cancer

Serum Analysis Confirms Poor Tamoxifen Adherence Among Premenopausal Breast Cancer Patients

  • 20 Oct 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

A discrepancy has been detected between self-reported adherence to tamoxifen treatment and serum levels of the drug in premenopausal breast cancer patients...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Serum Analysis Confirms Poor Tamoxifen Adherence Among Premenopausal Breast Cancer Patients

Anticancer agents - Prostate Cancer

Optimal Radiation–ADT Regimen Still Unclear For Intermediate–High-Risk Localised PC

  • 17 Oct 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

After more than 8 years of follow-up, researchers favour whole-pelvic radiotherapy plus neoadjuvant hormone therapy for the treatment of intermediate- and high-risk localised prostate cancer...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Optimal Radiation–ADT Regimen Still Unclear For Intermediate–High-Risk Localised PC

Breast Cancer - Surgical oncology

Autologous Fat Transfer Link To Breast Cancer Recurrence Refuted

  • 12 Oct 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Research has found no evidence that autologous fat transfer reconstruction is associated with an increased risk of breast cancer recurrence compared with conventional techniques...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Autologous Fat Transfer Link To Breast Cancer Recurrence Refuted

Lymphomas - Biological therapy

Chemotherapy-Free Approach To Indolent Lymphoma Retains Overall Survival

  • 10 Oct 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Not all patients with symptomatic indolent lymphomas will require chemotherapy after initial first-line treatment with rituximab...

view detailsof Chemotherapy-Free Approach To Indolent Lymphoma Retains Overall Survival

Aetiology, epidemiology, screening and prevention - Colon and Rectal Cancer - Complications/Toxicities of treatment - Surgical oncology

Screen-Detected Colon Cancer Postoperative Outcomes ‘Better’

  • 05 Oct 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Patients are less likely to experience complications after colon cancer surgery when the disease was detected during a national screening programme than by another route...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Screen-Detected Colon Cancer Postoperative Outcomes ‘Better’

Immunotherapy - Non-small-cell lung cancer

Pembrolizumab Achieves Survival Improvements Across PD-L1 Status In KEYNOTE-407 Trial

  • 28 Sep 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Adding pembrolizumab to chemotherapy boosts survival of patients with treatment-naïve, squamous non-small-cell lung cancer that has metastasised, regardless of PD-L1 tumour proportion score...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Pembrolizumab Achieves Survival Improvements Across PD-L1 Status In KEYNOTE-407 Trial

Immunotherapy - Non-small-cell lung cancer

PACIFIC Update Demonstrates Durvalumab OS Benefit For Stage III Inoperable NSCLC

  • 27 Sep 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Overall survival is longer with durvalumab than placebo for patients with unresectable stage III non-small-cell lung cancer that has not progressed after chemoradiation...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof PACIFIC Update Demonstrates Durvalumab OS Benefit For Stage III Inoperable NSCLC

Anticancer agents - Clinical research - Soft Tissue Sarcomas

‘Encouraging’ Early Results For Trabectedin Plus Olaparib In Soft-Tissue Sarcoma

  • 17 Sep 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Preliminary findings suggest that a combination of trabectedin and olaparib may be feasible for patients with soft-tissue sarcoma that has progressed after conventional treatment...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof ‘Encouraging’ Early Results For Trabectedin Plus Olaparib In Soft-Tissue Sarcoma

Anticancer agents - Colon and Rectal Cancer

TAILOR Supports Cetuximab–FOLFOX-4 For RAS Wild-Type Metastatic Colorectal Cancer

  • 13 Sep 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

The addition of cetuximab to FOLFOX-4 chemotherapy may significantly improve the survival of patients with RAS wild-type metastatic colorectal cancer...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof TAILOR Supports Cetuximab–FOLFOX-4 For RAS Wild-Type Metastatic Colorectal Cancer

Anticancer agents - Haematologic Malignancies - Lymphomas

Rituximab Combination Efficacy Equal For First-Line Advanced Follicular Lymphoma

  • 07 Sep 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

The rate of response to first-line treatment for advanced follicular lymphoma does not significantly differ with rituximab plus lenalidomide and rituximab with chemotherapy...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Rituximab Combination Efficacy Equal For First-Line Advanced Follicular Lymphoma

Immunotherapy - Oesophageal Cancer - Gastric Cancer

Nivolumab, Nivolumab Plus Ipilimumab ‘Supported’ For Western Refractory Oesophagogastric Cancer Patients

  • 05 Sep 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

CheckMate-032 findings indicate patients with chemotherapy-refractory oesophagogastric cancer in the USA and Europe may benefit from nivolumab given alone or alongside ipilimumab...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Nivolumab, Nivolumab Plus Ipilimumab ‘Supported’ For Western Refractory Oesophagogastric Cancer Patients

Anticancer agents - Hepatobiliary Cancers - Therapy

Nab-Paclitaxel Plus Gemcitabine Could Be An Option For Advanced Cholangiocarcinoma

  • 03 Sep 2018
  • Author : By Shreeya Nanda, Senior medwireNews Reporter

Phase II trial results indicate nab-paclitaxel plus gemcitabine might offer an alternative to the current therapeutic options for treatment-naive advanced or metastatic cholangiocarcinoma...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Nab-Paclitaxel Plus Gemcitabine Could Be An Option For Advanced Cholangiocarcinoma

Anticancer agents - Genitourinary Cancers - Urothelial Cancers - Therapy

Neoadjuvant Dose-Dense MVAC May Improve Bladder Cancer Outcomes

  • 31 Aug 2018
  • Author : By Shreeya Nanda, Senior medwireNews Reporter

A US chart review adds to the evidence for the neoadjuvant use of dose-dense methotrexate, vinblastine, doxorubicin and cisplatin in patients with muscle-invasive bladder cancer...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Neoadjuvant Dose-Dense MVAC May Improve Bladder Cancer Outcomes

Non-small-cell lung cancer - Personalised/Precision medicine - Therapy

Osimertinib Reduces CNS Progression Risk In Advanced EGFR Mutation-Positive NSCLC

  • 30 Aug 2018
  • Author : By Shreeya Nanda, Senior medwireNews Reporter

Osimertinib has central nervous system efficacy in patients with treatment-naïve locally advanced or metastatic non-small-cell lung cancer positive for activating EGFR mutations...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Osimertinib Reduces CNS Progression Risk In Advanced EGFR Mutation-Positive NSCLC